INCY · CIK 879169
What Incyte Corporation told the SEC could break it.
Incyte's register centers on a fragile, single-source supply chain for its biggest products. The raw materials for ruxolitinib phosphate — the active ingredient in JAKAFI and OPZELURA, its largest product — come from Chinese-based suppliers, so a U.S.-China trade dispute or Chinese government action could choke that supply (it is qualifying a European alternative for later in 2026); and more broadly, it operates almost no manufacturing of its own and relies on single or limited contract manufacturers for each drug's API and finished product, where a sole-source failure could halt commercial supply or clinical trials. On top of that, the Inflation Reduction Act's Medicare price-negotiation and inflation-rebate provisions pressure the U.S. prices it can charge.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- China-sourced ruxolitinib API raw materials (trade dispute)high
Raw materials for ruxolitinib phosphate — the API in JAKAFI and OPZELURA (Incyte's largest product) — are supplied by Chinese-based companies; a US-China trade dispute or Chinese government action could cut supply (Incyte is qualifying a European supplier for later-2026 use).
“currently raw materials used to manufacture ruxolitinib phosphate, the API in JAKAFI and OPZELURA, are supplied by Chinese-based companies. As a result, an international trade dispute between China and the United States or any other actions by the Chinese government that would limit or prevent Chinese companies from supplying these materials would adversely affect our ability to manufacture and supply our products to meet market needs and have a material and adverse effect on our operating results.”
- IRA Medicare drug-price negotiation / inflation rebatesmedium
The Inflation Reduction Act lets the federal government negotiate prices for high-expenditure single-source Medicare drugs (with penalties/excise tax for non-compliance) and imposes inflation-rebate liability on above-inflation price increases, pressuring Incyte's US product pricing.
“in August 2022, the Inflation Reduction Act of 2022 was enacted, which includes provisions allowing the federal government to negotiate prices for certain high-expenditure single source Medicare drugs, to impose penalties and to implement a potential excise tax for manufacturers that fail to comply with the negotiation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law, and to impose rebate liability on manufacturers that take price increases that exceed inflation.”
Sole-source dependency
- single/limited-source API and finished-drug-product manufacturershigh
Incyte has single or limited qualified contract manufacturers for the API and finished product of each drug (it operates no manufacturing for most products); a sole-source supplier's inability to supply compliant API/finished product could halt commercial supply or clinical trials.
“We generally have a single source or a limited number of suppliers that are qualified to supply each of the API and finished product of our drug products and our other drug candidates. ... If any of these single source suppliers were to become unable or unwilling to supply us with API or finished product that complies with applicable regulatory requirements, we could incur significant delays in our clinical trials or interruption of commercial supply which could have a material adverse effect on our business.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We currently rely on third-party contract manufacturers as well as Incyte for all of our required raw materials, active pharmaceutical ingredients and finished product for our preclinical research, clinical trials, and commercial supply.”
Cited →“We also are eligible to receive tiered, double-digit royalties ranging from the upper-teens to the mid-twenties on future JAKAVI (the trade name used by Novartis for ruxolitinib sales outside of the United States) net sales outside of the United States, and tiered, worldwide royalties on TABRECTA net sales that range from 12 % to 14 %. Product royalty revenue related to Novartis' net sales of JAKAVI outside of the United States for the years ended December 31, 2025, 2024 and 2023 was $ 457.7 million, $ 418.8 million and $ 367.6 million, respectively.”
Cited →
Its suppliers
“Incyte leads the commercialization of axatilimab globally and we are co-commercializing Niktimvo in the United States.”
Cited →“We and Syndax have agreed to co-develop axatilimab and to share development costs associated with global and U.S.-specific clinical trials, with Incyte responsible for 55 % of such costs and Syndax responsible for 45 % of such costs.”
Cited →“We are responsible for the sourcing and manufacturing of ZYNYZ together with our collaborator MacroGenics.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch